Loading clinical trials...
Loading clinical trials...
A Modular, Multipart, Multiarm, Open-label, Phase I/II Study to Evaluate the Safety and Tolerability of CT7001 Alone and in Combination With Anti-cancer Treatments in Patients With Advanced Malignancies
Conditions
Interventions
CT7001
Fulvestrant
Locations
23
United States
Research Site 54
Tucson, Arizona, United States
Research Site 31
Beverly Hills, California, United States
Research Site 37
Tampa, Florida, United States
Research Site 38
Chicago, Illinois, United States
Research Site 34
Boston, Massachusetts, United States
Research Site 47
Cincinnati, Ohio, United States
Start Date
November 14, 2017
Primary Completion Date
December 15, 2022
Completion Date
December 15, 2022
Last Updated
November 12, 2025
NCT06927297
NCT06760481
NCT04521413
NCT05573724
NCT02347228
NCT02439723
Lead Sponsor
Carrick Therapeutics Limited
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions